Rosa Lapalombella
Has grant
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Close
Understanding Richter's Transformation in the targeted therapies era
Open Date: 2020-09-11
Close Date: 2025-05-31
Grant: Close
Targeting NAMPT in Acute Myeloid Leukemia
Open Date: 2018-08-02
Close Date: 2025-07-31
Grant: Close
Targeted Therapies for Richters Transformation
Open Date: 2017-02-07
Close Date: 2022-01-31
Grant: Close
Pathogenesis and Treatment of Richter’s Transformation
Open Date: 2017-01-01
Close Date: 2020-12-31
Grant: Close
Dual targeting of XPO1 and BTK in B cell malignancies
Open Date: 2015-04-21
Close Date: 2021-03-31
Articles (28)
Year:
2026
Year:
2026
Year:
2026
Inhibition of the tyrosine kinase BTK is a major therapeutic strategy for treating B-cell malignancies, including chronic lymphocytic leukemia (CLL). However, resistance can emerge when tumor cells acquire mutations that abrogate drug binding or when BTK activates B-cell receptor (BCR) signaling by mechanisms independent of its kinase activity. In this study, we identified upregulation of PKCβ in samples from patients with CLL resistant to BTK inhibitors (BTKi) and characterized the PKCβ inhibitor MS-553. MS-553 reduced BCR and Wnt/β-catenin signaling, overcame stromal cell mediated protection, and synergized with venetoclax in CLL samples. MS-553 also retained the cytotoxicity and inhibition of both BCR and Wnt/β-catenin signaling in models (cell lines and primary samples) of covalent BTKi-resistant (C481S BTK ) and noncovalent BTKi-resistant (T474I or L528W BTK ) CLL. Furthermore, MS-553 delayed disease progression and prolonged survival in the Eμ-MTCP1 murine model of CLL. Collectively our results demonstrate that selective inhibition of PKCβ has the potential to overcome BTKi-resistant CLL. Significance: This study identified and characterized PKCβ as a therapeutic target in CLL, including CLL resistant to BTKis. Inhibition of PKCβ suppressed both BCR and Wnt/β-catenin signaling, delayed disease progression in vivo , overcame BTKi resistance mechanisms, and enhanced response to BCL-2 inhibition. See related commentary by Jebaraj and Stilgenbauer, p. 21
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2022
Collaborators (28)
Alice Mims
Ohio State University
Cem Meydan
Assistant Professor
Weill Cornell Medicine
Marlise Luskin
Dana-Farber Cancer Institute
Girish Venkataraman
Asst Professor
University of Chicago Pritzker School of Medicine
Walter Hanel
Ohio State University
Robert Baiocchi
-
Sandeep Gurbuxani
Professor
University of Chicago
Anand Ashwin Patel
Assistant Professor of Medicine
-
Adam Sperling
Assistant Professor
Stanford University
Benjamin Ebert
Dana-Farber Cancer Institute
Lapo Alinari
Ohio State University
Lachelle Dawn Weeks
Dana-Farber Cancer Institute
chunhua song
Associate Professor
Ohio State University
Satishkumar Singh
Ohio State University
Samir Parekh
Director, Center of Excellence for Multiple Myeloma
Icahn School of Medicine at Mount Sinai
Daniel Arber
Professor and Chair
University of Chicago
Ulrich Steidl
Albert Einstein College of Medicine
Lucy A. Godley
Northwestern Medicine
Wing Keung Chan
Assistant Professor
Ohio State University
Peng Wang
Associate professor
University of Chicago Medicine
Robert Faryabi
Associate Professor
University of Pennsylvania
Wendy Stock
Professor of Medicine
University of Chicago
John Greally
Director, New York Center for Rare Diseases (NYCRD)
Albert Einstein College of Medicine
Richard Larson
Professor
University of Chicago
Angela Lager
Assistant Professor
University of Chicago
Lalit Sehgal
Associate Professor
Ohio State University
Violetta Leshchenko
Senior Scientist
Icahn School of Medicine at Mount Sinai
Christopher Mason
Professor
Weill Cornell Medical College
Make your next move.
Prepare your application
Review drafts before you send them.